tients undergoing percutaneous coronary intervention (PCI), and in patients with ACS are associated with short-term mortality and morbidity, prolonged length of stay and greater resource consumption. 3 -5 Consequently, inclusion of bleeding as a safety endpoint in randomized controlled trials (RCTs) is essential for the assessment of new antithrombotic agents and interventional techniques.
In past studies, a large number of bleeding classifications have been used to report bleeding complications (an overview of current bleeding classifications is presented in Supplementary material online, Table S1 ). This variety has hampered direct comparison of incidences of bleeding complications across different trials or even within studies, because reported bleeding incidences may vary widely according to the applied bleeding definition. 6, 7 To overcome the heterogeneity in bleeding definitions, the Bleeding Academic Research Consortium (BARC) has developed a standardized hierarchical bleeding classification system. 8 The prognostic value of BARC defined bleeding complications was recently established in patients undergoing elective PCI, in patients with ACS and in those with ST-segment elevation myocardial infarction (STEMI). 9 -11 Introduction of standardized bleeding classifications represents a first step to improved interpretation of safety results from clinical trials and registries. Bleeding rates, however, depend on several factors, including how aggressively investigators seek to track bleeding events, and on how definitions are written and applied. Previous studies conducted in similar study populations, using similar treatment strategies, and using identical study methodology have shown great disparities in bleeding incidences, even when identical bleeding definitions were applied. To illustrate this, we provide an overview of RCTs reporting Thrombolysis in Myocardial Infarction (TIMI) major or minor bleeding rates for STEMI patients undergoing primary percutaneous coronary intervention (PPCI). To minimize the effect of differential bleeding profiles of different antithrombotic agents, we only present studies reporting TIMI bleeding rates for STEMI patients undergoing PPCI with unfractionated heparin (UFH), aspirin, and clopidogrel. We performed a computerized literature search from 1 January 2001 to 25 May 2015 of the PubMed and Embase database, using search terms that included 'percutaneous coronary intervention' or 'percutaneous transluminal coronary angioplasty' or 'primary percutaneous coronary intervention' or 'primary angioplasty', and ''myocardial infarction'' or 'ST-segment elevation myocardial infarction' or 'ST-segment elevation acute coronary syndrome'. Citations were screened at title/abstract level and retrieved as full reports. Bibliographies of identified studies and relevant review articles were screened for potentially suitable studies. Non-English articles, case reports, non-randomized studies, reviews and studies reporting duplicate data were excluded. To be included, studies had to present TIMI major or minor bleeding rates for patients treated with PPCI with UFH, aspirin, and clopidogrel. The flowchart of the search strategy can be found in Supplementary material online, Figure S1 . In total, we identified 15 studies presenting TIMI major or minor bleeding rates for STEMI patients undergoing PPCI with UFH, aspirin, and clopidogrel. Table 1 provides an overview of these studies, including the prevalence of some important correlates of bleeding and TIMI bleeding rates. In patients treated with PPCI by the transfemoral approach and glycoprotein IIb/IIIa inhibitors in hospital or 30-day TIMI major bleeding rates ranged from 0.8 to 9.5% and TIMI minor bleeding ranged from 1.2 to 12.9%. Likewise, in STEMI patients undergoing PCI by the transfemoral route with restricted use of GP IIB/IIIA inhibitors (,13%) in-hospital or 30-day TIMI major bleeding varied between 1.8 and 5.5% and TIMI minor varied between 1.8 and 9.1%. Figures 1 -3 illustrate how strongly TIMI major and minor bleeding rates differ for the studies reported in Table 1 . Differences in bleeding rates can be explained by several factors, including differences in local practice, baseline variables and unmeasured confounders. Moreover, differences in the percentage of vascular closure device use might have impacted on the diverging bleeding rates among the reported studies. However, the incidence of bleeding complications also relies heavily on the amount and the quality of the acquired source documentation and on adjudication. Table 1 . The diameter of the bubbles indicates sample size. Abbreviations as in Table 1 . Differences in adjudication may arise in difficult cases in which bleeding classifications leave room for free interpretation by the clinical event committee (CEC). Box 1 provides four illustrative cases in which differences in adjudication may occur. Case 1 demonstrates that it can be challenging to calculate the haemoglobin (Hb) decrease in a patient presenting at a healthcare facility with a gastrointestinal bleeding, because it is currently unclear which Hb measurement should be considered 'baseline', and which measurement 'nadir'. Moreover, an Hb decrease without overt bleeding occurs relatively frequently in patients with ACS, possibly as a result of haemodilution (e.g. after intravenous fluid resuscitation). 10, 12, 13 This complicates the adjudication of bleeding events according to bleeding definitions defined by an Hb decrease. In patients who develop a decrease in Hb or haematocrit due to haemodilution and who coincidentally develop a bleeding complication, one cannot determine whether the Hb decrease was the result of haemodilution, the bleeding event or both (Case 4 in Box 1 illustrates this). This results in overestimation of the severity of the bleeding and an increase in the prognostic value for mortality. Since one cannot discriminate whether the Hb decrease was the result of haemodilution or bleeding, the association between bleeding and mortality, might thus be confounded by the high mortality in patients who require fluid resuscitation (e.g. cardiogenic shock, right ventricle infarction). Case 3 in Box 1 illustrates that it can be challenging to determine if a bleeding complication resulted in hypotension requiring the use of vasoactive agents in a patient previously treated with vasoactive agents because of cardiogenic shock. Since one cannot discriminate whether the vasoactive agents were given for the bleeding event or for cardiogenic shock, the association between bleeding and mortality may be confounded by the prescription of vasoactive agents for cardiogenic shock, which is by itself associated with high mortality.
Recommendations for improvement
Our ability to compare bleeding events between trials could be improved if data collection and adjudication would be performed by a standardized approach. Supplementary material online, Table S2 provides a few recommendations for standardized data collection. Table 2 provides an overview of some challenges in adjudication along with recommendations which might offer guidance in the adjudication of bleeding events and contribute to a standardized Box 1 Examples of cases in which differences in bleeding rates may occur after adjudication Case 1.
A 76-year-old woman is admitted to a coronary care unit (CCU) because of an acute coronary syndrome. She develops a hematoma of 3 cm in the right groin after PCI. No intervention is required and hospitalization is not prolonged. Two days after PCI several laboratory measurements are obtained, including Hb. From the available source documentation, it is indistinguishable whether these laboratory measurements were acquired as part of routine clinical care, or because of the minor bleeding event. In this situation, one cannot determine whether this bleeding event qualifies as BARC 2 or BARC 1, since it is impossible to determine whether the Hb measurement was routine, or was prompted by the minor haematoma.
Case 2.
A 72-year-old male patient is admitted to a CCU with an acute coronary syndrome. His admission Hb measurement is 13.6 g/dL. He is discharged 4 days later after a conservative approach with an Hb of 12.8 g/dL. Three months later he develops a community acquired pneumonia for which he is admitted to the internal medicine department, where he is treated with intravenous antibiotics. His Hb decreases from 12.2 to 11.4 g/dL during this admission, possibly secondary to the infection as well as intravenous fluid resuscitation. He is readmitted to the CCU 22 days after the initial discharge with unstable angina, caused by anaemia secondary to gastrointestinal bleeding. At readmission his Hb was 6.8 g/dL. He then receives 3 units of packed red blood cells and his Hb levels subsequently rise.
If one considers 11.4 to be his baseline Hb, the Hb decrease would be 4.6 g/dL and one would adjudicate this bleeding as BARC 3A or TIMI minor bleeding. If one considers 13.6 g/dL to be his baseline Hb, the associated Hb decrease would be 6.8 g/dL and the bleeding would meet the BARC 3B and TIMI major bleeding criteria. If one considers 6.8 g/dL to be his baseline Hb measurement, then no Hb decrease occurred and the bleeding would meet the BARC 3A and TIMI minimal bleeding definition.
Case 3.
A 68-year-old male patient with STEMI caused by occlusion of the proximal left anterior descending artery is admitted to the intensive care unit (ICU) with cardiogenic shock after PPCI. He is treated with intra-aortic balloon counterpulsation (IABP) and intravenous vasoactive agents. Approximately 13 h after admission to the ICU, he develops blood loss at the IABP access site. The associated Hb decrease is 4.8 g/dL and he receives 3 units of packed red blood cells (PRBCs). The patient remains haemodynamically unstable for another 2 days, but dose increase in vasoactive agents is not required.
One could argue that, since increase in the dose of intravenous inotropes was not necessary after onset of bleeding, this bleeding event did not meet the criteria for BARC 3B and consequently would be adjudicated as BARC 3A. However, one could also argue that, because of the bleeding event a dose reduction in intravenous vasoactive agents was initially not possible. Thus the bleeding event contributed to prolonged inotrope dependency and thus should be classified as BARC 3B.
Case 4.
A 64-year-old man with a history of peripheral artery disease is treated with PPCI with drug eluting stent implantation of the proximal right coronary artery because of inferior wall myocardial infarction with right ventricle involvement. His admission Hb measurement is 14.2 g/dL. After the procedure, he develops a groin haematoma 7 cm in diameter, requiring no further intervention. Because of right ventricle failure, he receives aggressive fluid resuscitation. The nadir Hb measurement is 11.0 g/dL.
Based on the case history, the 3.2 g/dL decrease in Hb is likely the result of a combination of haemodilution and blood loss in the right groin. Unfortunately, one cannot determine which part of the 3.2 g/dL decrease is related to the bleeding. Therefore, this bleeding event meets the criteria for BARC type 3A or TIMI minor bleeding (Hb decrease between 3 and 5 g/dL), and GUSTO mild bleeding. Surgery to control bleeding is defined as any emergency surgical procedure (within 48 h of the bleeding event-excluding dental/nasal/skin/haemorrhoid surgery) performed with the direct goal of gaining immediate control of the bleeding DAPT, dual antiplatelet therapy; MAP, mean arterial pressure; IABP, intra-aortic balloon pump; PRBC, packed red blood cells; MI, myocardial infarction. Other abbreviations as in Table 1 .
